Management of Type 1 Diabetes in Children

1. Diagnosis and Initial Presentation

• Diabetic ketoacidosis (DKA) at diagnosis is more common in children under 5 years and in those with limited access to healthcare - globally, 13-80% of T1DM patients present with DKA at diagnosis
• Autoantibodies (anti-GAD65, anti-IA-2, anti-ZnT8, anti-insulin) confirm autoimmune etiology and help distinguish from T2DM
• The honeymoon/partial remission phase follows initial insulin treatment, when residual beta-cell function temporarily reduces insulin requirements - this can last weeks to months
• Puberty is associated with worsening glycemic control due to growth hormone and sex hormone-driven insulin resistance
• Goldman-Cecil Medicine, p. 2473

2. Glycemic Targets (ISPAD 2024 / ADA 2025)

3. Insulin Therapy - The Cornerstone of Management

Insulin Types and Pharmacokinetics

• Goldman-Cecil Medicine, insulin table

Recommended Regimens in Children

1. Basal-bolus MDI (Multiple Daily Injections): Long-acting basal insulin (glargine, detemir, or degludec) + rapid-acting prandial boluses before each meal. This mimics normal physiology most closely.
2. Continuous Subcutaneous Insulin Infusion (CSII) / Insulin Pump: Preferred approach. Delivers programmable basal rates + meal boluses. Reduces HbA1c by 0.3-0.5% and reduces severe hypoglycemia risk compared to MDI.
3. Automated Insulin Delivery (AID) / "Closed-Loop": Combines CSII with continuous glucose monitoring (CGM) and an algorithm that automatically adjusts insulin delivery in real time. This represents the current state of the art and is strongly recommended by ISPAD 2024 when available.

• Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 1053

4. Continuous Glucose Monitoring (CGM)

• Measures interstitial glucose every 1-5 minutes via subcutaneous sensor
• Can connect to insulin pump for automated delivery (AID systems)
• Provides time-in-range data which is more informative than HbA1c alone
• Sensor-augmented pumps can suspend insulin delivery when hypoglycemia is predicted ("low glucose suspend")
• For children using CGM, finger-stick capillary glucose is still needed to calibrate some devices and verify readings before treatment decisions

5. Medical Nutrition Therapy (MNT)

• Carbohydrate counting is the preferred approach: an insulin-to-carbohydrate ratio (ICR) is established for each child so that prandial insulin dose is matched to carbohydrate intake at each meal
• No single "diabetic diet" is mandated - emphasis is on whole grains, vegetables, lean protein, and avoidance of sugar-sweetened beverages
• Meals should be consistent in timing and composition to support predictable glycemic patterns
• A registered dietitian with pediatric and diabetes expertise should be part of the care team
• Goldman-Cecil Medicine (carbohydrate counting)

6. Physical Activity and Exercise

• Target: ≥150 min/week moderate aerobic activity (ADA)
• Risks: Both hypoglycemia (during/after prolonged aerobic exercise) and hyperglycemia (during intense anaerobic exercise due to catecholamine surges)
• Strategies:
  • Check glucose before, during, and after exercise
  • Delay exercise if glucose >14 mmol/L (250 mg/dL) with ketones
  • Ingest carbohydrates if pre-exercise glucose <5.0 mmol/L (90 mg/dL)
  • Reduce basal rates (pump) or inject in non-exercising areas
  • Post-exercise hypoglycemia can occur up to 12-24 hours later ("late hypoglycemia")
• EASD/ISPAD 2025 position statement specifically addresses AID system use around physical activity

7. DKA Management in Children

• Fluid resuscitation: Initial 10-20 mL/kg isotonic saline bolus for shock; subsequent rehydration over 24-48 hours (more cautious than adults to reduce cerebral edema risk)
• Insulin infusion: IV regular insulin at 0.05-0.1 units/kg/hr; do NOT start until after fluid resuscitation begins
• Potassium replacement: Critical - add to fluids once urine output confirmed (IV insulin drives K+ intracellularly)
• Do NOT use bicarbonate routinely in children
• Cerebral edema: The most feared complication in pediatric DKA; manifested by headache, deteriorating consciousness, bradycardia, hypertension. Risk factors include younger age, higher osmolarity, bicarbonate use, and overly rapid rehydration. Treat with mannitol or hypertonic saline immediately.
• Tintinalli's Emergency Medicine; Goldman-Cecil Medicine

8. Hypoglycemia

• Most common acute complication; risk increases with tight glycemic control
• Hypoglycemia unawareness: Loss of warning symptoms from repeated hypoglycemic episodes - blunts counterregulatory responses; more dangerous in young children who cannot communicate symptoms
• Mild-moderate (conscious, able to swallow): 15g fast-acting carbohydrate (glucose tablets, juice), recheck in 15 min ("15-15 rule")
• Severe (loss of consciousness): IM/SC glucagon (available as auto-injector for home use); IV dextrose in hospital
• Nocturnal hypoglycemia is a particular concern; CGM with alarms is invaluable

9. Screening for Complications

10. Psychosocial Care and the Multidisciplinary Team

• Diabetes distress, depression, and anxiety are significantly more common than in healthy peers
• Screening for eating disorders (especially in adolescent girls) is important, as insulin omission for weight control ("diabulimia") worsens outcomes dramatically
• A multidisciplinary team should include: pediatric endocrinologist, diabetes educator, dietitian, psychologist/social worker, and primary care provider
• Family involvement is central to success, particularly in younger children (parents manage insulin and monitoring)
• Transition to adult care is a vulnerable period and requires structured planning beginning in early adolescence
• Harrison's Principles of Internal Medicine 22E, p. 3250

11. Emerging Therapies

• Teplizumab (anti-CD3 antibody): FDA-approved (2022) for delaying onset of clinical T1DM in at-risk individuals (Stage 2 disease). Represents the first disease-modifying therapy.
• AID (Closed-Loop) Systems: Multiple FDA-approved systems (e.g., MiniMed 780G, Tandem Control-IQ, Omnipod 5) - ISPAD 2024 strongly endorses their use as they significantly improve TIR and reduce hypoglycemia
• Beta-cell preservation: Ongoing trials with immunotherapy to preserve residual beta-cell function at diagnosis
• Ultra-rapid insulins: Fiasp (faster aspart), Lyumjev (ultra-rapid lispro) - may improve postprandial control in AID systems
• EASD/ISPAD 2025 published a joint position statement on AID use during exercise [PMID: 39653802]

Key Takeaways

1. Insulin is mandatory and lifelong - intensive basal-bolus or CSII regimens are standard
2. AID (closed-loop) systems are the current optimal approach when accessible
3. HbA1c ≤7.0% is the general target, with TIR >70% as the preferred metric
4. DKA risk is highest in children under 5 and requires careful, pediatric-specific protocols
5. Hypoglycemia awareness and prevention, especially nocturnal, are critical
6. Regular screening for complications and comorbidities begins at diagnosis
7. Psychosocial support for child and family is integral, not optional

Recent evidence update: A 2025 EASD/ISPAD consensus statement on AID use during physical activity provides updated guidance specific to children and adolescents [PMID: 39653802]. The 2024 ISPAD Clinical Practice Consensus Guidelines updated chapters on glycemic targets, insulin therapies, and diabetes technologies are the current global reference standard for pediatric T1DM management.